Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro.
Animals
Antiviral Agents
/ pharmacology
Caliciviridae Infections
/ drug therapy
Calicivirus, Feline
/ drug effects
Cat Diseases
/ drug therapy
Cats
Cell Line
Drug Synergism
Female
Lung
/ drug effects
Nitro Compounds
/ pharmacology
Ribonucleosides
/ pharmacology
Thiazoles
/ pharmacology
Trachea
/ drug effects
Viral Load
/ drug effects
Virus Shedding
/ drug effects
Antiviral
Feline calicivirus
In vivo
Mizoribine
Nitazoxanide
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
29
12
2019
revised:
14
04
2020
accepted:
27
05
2020
pubmed:
25
6
2020
medline:
13
7
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Feline calicivirus (FCV) is a highly contagious pathogen that causes acute upper respiratory infections and oral disease in cats, thus seriously endangering feline health. Recently, there have been outbreaks of particularly virulent variant strains of FCV, which can cause both acute symptoms and fatal systemic disease. The discovery of effective antiviral agents to treat FCV infection is, therefore, gradually assuming increased importance. In this study, we showed that both nitazoxanide and mizoribine had antiviral activity in F81 cells infected with different strains of FCV and also demonstrated a synergistic effect between the two drugs. Experiments in cats challenged with FCV showed that nitazoxanide significantly reduced the clinical symptoms of FCV infection, reduced viral load in the trachea and lungs, and reduced viral shedding. Our results showed that nitazoxanide and mizoribine could potentially be used as therapeutic agents to treat FCV infection.
Identifiants
pubmed: 32579897
pii: S0166-3542(20)30241-2
doi: 10.1016/j.antiviral.2020.104827
pmc: PMC7306210
pii:
doi:
Substances chimiques
Antiviral Agents
0
Nitro Compounds
0
Ribonucleosides
0
Thiazoles
0
mizoribine
4JR41A10VP
nitazoxanide
SOA12P041N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104827Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Int Immunopharmacol. 2019 Oct;75:105714
pubmed: 31352323
Antivir Chem Chemother. 2002 Nov;13(6):345-52
pubmed: 12718406
iScience. 2019 Sep 27;19:1279-1290
pubmed: 31402258
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13
pubmed: 26949479
Viruses. 2019 Mar 21;11(3):
pubmed: 30901945
Vaccine. 2017 May 9;35(20):2753-2760
pubmed: 28389099
J Infect Dis. 2017 Sep 15;216(6):780-782
pubmed: 28934433
Viruses. 2019 Jul 31;11(8):
pubmed: 31370359
Arch Virol. 2016 Jun;161(6):1559-67
pubmed: 26997613
Arch Virol. 2017 Sep;162(9):2579-2589
pubmed: 28478577
Infect Genet Evol. 2018 Nov;65:425-429
pubmed: 30176370
Antiviral Res. 2005 Jun;66(2-3):159-63
pubmed: 15911031
J Gen Virol. 2017 Jul;98(7):1730-1738
pubmed: 28691897
Bioinformatics. 2017 Aug 1;33(15):2413-2415
pubmed: 28379339
J Infect. 2011 Nov;63(5):394-7
pubmed: 21839773
J Food Prot. 2016 Jun;79(6):1001-12
pubmed: 27296605
Vet Pathol. 2011 Mar;48(2):361-8
pubmed: 20634409
Expert Opin Investig Drugs. 2000 Feb;9(2):221-35
pubmed: 11060673
Res Vet Sci. 2017 Apr;111:120-123
pubmed: 28235707
Res Vet Sci. 2019 Jun;124:46-51
pubmed: 30844542
Molecules. 2019 May 03;24(9):
pubmed: 31058822
Curr Med Chem. 1999 Jul;6(7):575-97
pubmed: 10390602
Viruses. 2018 Aug 16;10(8):
pubmed: 30115859
Int J Biol Macromol. 2017 Feb;95:160-167
pubmed: 27865960
Viruses. 2019 May 30;11(6):
pubmed: 31151251
Berl Munch Tierarztl Wochenschr. 2011 May-Jun;124(5-6):186-93
pubmed: 22059287
Transplant Proc. 1990 Aug;22(4):1682-5
pubmed: 2167528
Antiviral Res. 2018 Apr;152:76-83
pubmed: 29454892
Vet Rec. 2011 Jun 4;168(22):585-6
pubmed: 21642309
Viruses. 2019 Aug 13;11(8):
pubmed: 31412574